This project has received funding from the European Union’s HORIZON EUROPE Coordination and Support Actions under grant agreement no 101059870
Adverse drug reactions kill hundreds of thousands of patients every year in Europe alone. Hence the development of pharmacogenomics (PGX) to personalise therapies to improve the outcomes of the treatments is of great importance. The EU-funded PharmGenHUB project will support the effort of several university partners, coordinated by the Institute of Molecular Genetics and Genetic Engineering at the University of Belgrade in Serbia to develop PGX diagnostics, education, training, and translation of PGX knowledge into digital solutions for medical applications in the Western Balkans (WB) region. The project will employ high-throughput DNA sequencing to identify WB-specific drug-PGX marker pairs and to design electronic tools for treatment individualisation in clinical practice.
PANEPISTIMIO PATRON (UPAT), The Laboratory of Pharmacogenomics and Individualized Therapy, Faculty of Pharmacy, Patras, Greece, prof George P. Patrinos
UNIVERZA V LJUBLJANI (UL), Pharmacogenetics Laboratory at the Institute of Biochemistry, Medical Faculty, Ljubljana, Slovenia, prof Vita Dolzan